Publications by authors named "A de Boer-Brand"
Article Synopsis
- The study investigates the implementation of dose reduction (DR) for biologic treatments in psoriasis patients across three hospitals over six months.
- It found that while the implementation strategy was generally followed, not all healthcare providers utilized the tools provided, indicating areas for improvement.
- Successful implementation of DR was linked to better patient support, guideline integration, and efficient electronic health systems, which helped 50% of eligible patients start DR.
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Lotte S Spekhorst Marlies de Graaf Nicolaas P A Zuithoff Juul M P A van den Reek Marijke Kamsteeg Astrid de Boer-Brand
JAMA Dermatol
September 2022
Article Synopsis
- Long-term data on the survival of dupilumab in patients with atopic dermatitis (AD) is limited, and there is a need to understand what factors influence its effectiveness over time.
- The study analyzed data from 715 adult patients in the Netherlands, showing that dupilumab had drug survival rates of 90.3%, 85.9%, and 78.6% at 1, 2, and 3 years, respectively.
- Factors linked to shorter drug survival included the use of immunosuppressants and being a nonresponder at 4 weeks, as well as age over 65 and severe forms of AD, indicating specific characteristics that could predict treatment outcomes.